Ascent Wealth Partners’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.43M Buy
15,898
+242
+2% +$37.1K 0.28% 80
2025
Q4
$2.16M Buy
15,656
+19
+0.1% +$2.49K 0.25% 80
2025
Q3
$2.01M Sell
15,637
-368
-2% -$44.9K 0.23% 87
2025
Q2
$1.94M Sell
16,005
-136
-0.8% -$15.3K 0.24% 85
2025
Q1
$1.8M Sell
16,141
-62
-0.4% -$6.6K 0.24% 88
2024
Q4
$1.58M Buy
16,203
+169
+1% +$18K 0.21% 87
2024
Q3
$1.84M Sell
16,034
-53
-0.3% -$6.01K 0.26% 82
2024
Q2
$1.71M Sell
16,087
-123
-0.8% -$12.3K 0.25% 85
2024
Q1
$1.57M Buy
16,210
+239
+1% +$24.5K 0.23% 83
2023
Q4
$1.61M Buy
15,971
+157
+1% +$15.2K 0.26% 73
2023
Q3
$1.61M Buy
15,814
+1,080
+7% +$110K 0.3% 67
2023
Q2
$1.49M Buy
14,734
+867
+6% +$86.7K 0.26% 79
2023
Q1
$1.28M Buy
13,867
+540
+4% +$47.2K 0.26% 85
2022
Q4
$1.21M Buy
13,327
+1,201
+10% +$101K 0.26% 86
2022
Q3
$922K Sell
12,126
-90
-0.7% -$7.46K 0.22% 89
2022
Q2
$1.04M Buy
12,216
+2,888
+31% +$253K 0.24% 85
2022
Q1
$818K Buy
9,328
+1,397
+18% +$121K 0.15% 93
2021
Q4
$693K Buy
7,931
+184
+2% +$15.3K 0.12% 101
2021
Q3
$634K Buy
7,747
+1,955
+34% +$176K 0.12% 109
2021
Q2
$528K Buy
+5,792
New +$516K 0.1% 108

Other funds holding NVS

Ascent Wealth Partners's NVS Position: Q1 2026 in Review

Ascent Wealth Partners increased its Novartis (NVS) stake by 1.5% in Q1 2026, buying an estimated $37.1K and bringing the position to 15,898 shares worth $2.43M. The position accounts for 0.28% of the portfolio, ranked #80.

Ascent Wealth Partners first reported a position in NVS in Q2 2021 and has held it in 20 quarters since. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Ascent Wealth Partners held 15,898 shares of Novartis worth $2.43M as of Q1 2026.
  • Ascent Wealth Partners bought 242 Novartis shares in Q1 2026, an estimated $37.1K.
  • Novartis made up 0.28% of Ascent Wealth Partners's portfolio in Q1 2026, its #80 holding.
  • Ascent Wealth Partners first reported a position in Novartis in Q2 2021 and has held it in 20 quarters since.
  • 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Ascent Wealth Partners's 13F filing for Q1 2026, filed 6 May 2026.